CEA Specific Neutra™ Antibody Products
Product listCEA (carcinoembryonic antigen) is a glycoprotein that is primarily found in the fetal colon and intestinal mucosa, but can also be produced by certain tumors. CEA plays a role in cellular adhesion and is thought to be involved in cell proliferation, differentiation, and migration.
Signaling Pathway of CEA
CEA has been implicated in several important signaling pathways, including the Wnt/β-catenin pathway, which regulates cell proliferation and differentiation, and the PI3K/Akt/mTOR pathway, which regulates cell survival and growth. Studies have suggested that CEA may activate these pathways by interacting with specific cell surface receptors, such as the epidermal growth factor receptor (EGFR) or the integrin alpha-5/beta-1.
Roles of CEA in Cancer and Other Diseases
CEA has been studied extensively in the context of cancer, where it is often used as a tumor marker to monitor disease progression and treatment response. Elevated CEA levels have been correlated to several kinds of cancers, including, breast, colorectal, pancreatic, and lung cancer. Mechanisms underlying the association between CEA and cancer are not entirely clear, but it is believed that CEA may promote tumor growth and metastasis by modulating cellular adhesion and signaling pathways. Aside from cancer, CEA has also been implicated in other diseases, such as inflammatory bowel disease (IBD), where it is thought to play a role in disease pathogenesis by modulating the immune response and promoting inflammation.
Fig.1 Various CEA interactions to support tumor progression and metastasis.1
Antibodies Against CEA
Antibodies against CEA have been developed as a potential immunotherapy strategy to specifically target and eliminate CEA-expressing cancer cells.
- Monoclonal antibodies
Monoclonal antibodies (mAbs) are engineered to recognize and bind to CEA with high specificity. They can block the interaction between CEA and its receptors, thus inhibiting signaling pathways that promote tumor growth and survival. The most well-known anti-CEA mAb, which has been approved by the FDA for the treatment of metastatic colorectal cancer, functions by binding to CEA and preventing its interaction with the EGFR. This disrupts downstream signaling pathways involved in tumor cell proliferation and survival. Other anti-CEA mAbs have also shown encouraging results in clinical studies for various types of cancers.
- Bispecific antibodies
Bispecific antibodies are a more recent development in CEA-targeted therapy. These antibodies are designed to simultaneously bind to CEA on tumor cells and to immune cells, such as T cells. This dual binding activates the immune cells and redirects them to specifically attack CEA-expressing cancer cells. Bispecific antibodies against CEA have shown the potential to boost the body's immune response to cancer cells, leading to tumor regression.
Creative Biolabs offers twenty-five different kinds of anti-CEA antibody products to meet your various research needs. These antibodies are recombinantly produced and can be used for eight different applications. Besides, CEA-based bispecific antibodies can be customized here.
REFERENCE
- Beauchemin, Nicole, and Azadeh Arabzadeh. "Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis." Cancer and Metastasis Reviews 32 (2013): 643-671.
